Clinical Trial Update: Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis [Phase 3]

View source ↗

Summary

Phase 3 trial results for ibrefungERp (Brexafemme) in the treatment of complicated vulvovaginal candidiasis have been completed, with results posted on 2024-07-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• Brexafemme (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Vulvovaginal Candidiasis | Phase 3 | Status: COMPLETED | Results posted: 2024-07-10